A Phase 2 Open-label Randomized, Controlled Trial of CS-1008 in Combination With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Oxaliplatin Based Regimen.

Trial Profile

A Phase 2 Open-label Randomized, Controlled Trial of CS-1008 in Combination With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Oxaliplatin Based Regimen.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2012

At a glance

  • Drugs Irinotecan; Tigatuzumab
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jul 2012 Planned number of patients changed from 80 to 92 as reported by EudraCT.
    • 18 Jul 2012 Company added in the association field as reported by EudraCT.
    • 30 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top